Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

An FDA First Adds To Rock Creek’s Regulatory Adventures

This article was originally published in The Tan Sheet

Executive Summary

FDA “for the first time” notified tobacco retailers about products found to be not substantially equivalent for sale, with each of the 16 warnings identifying Rock Creek’s Ariva and Stonewall Jackson nicotine lozenges. The firm continues turning its operations to drug development after FDA rejected a NDI notification.

You may also be interested in...



Between A Rock Creek And A Hard Place: Firm Stops Supplement Sales, Weathers Litigation

Rock Creek Pharmaceuticals faces investor and consumer class-action complaints on top of ending sales of its nutritionals following an FDA warning. Moreover, the company name is known more in connection with federal officials’ investigation of the former governor of Virginia than for its products.

US VMS Industry Makes Lame Duck Session List, Checks It Twice For MPL Language

AHPA urges chairs and ranking members of Senate HELP and House Energy and Commerce committees not to pass mandatory product listing legislation or make other changes to FDA regulation of industry before the 117th Congress ends. NPA board members lobby lawmakers about the topic.

Rx Naloxone Marketer's OTC Switch Proposal For Nasal Spray Gets Priority Review From FDA

Emergent BioSolutions’ announcement of FDA accepting sNDA for an OTC 4-mg naloxone nasal spray marks another recent step in agency’s response under Commissioner Califf to Capitol Hill pressure to expand availability of topioid antagonist to help curb opioid overdose death epidemic.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS107303

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel